Treatment with the combination of the CD47-targeting antibody magrolimab and azacitidine induced high response rates, particularly in patients with myelodysplastic syndromes. David A. Sallman, MD, discusses findings from an ongoing phase Ib trial.
Recent Articles
European Commission Approves Selinexor Plus Dexamethasone for Relapsed/Refractory Myeloma
Selinexor, in combination with dexamethasone, has been granted conditional marketing authorization by the European Commission (EC) for the treatment of adult patients with multiple...
FDA Approves Isatuximab-irfc Combination for Relapsed/Refractory Myeloma
Isatuximab-irfc, in combination with carfilzomib and dexamethasone (Isa-Kd), was approved by the U.S. Food and Drug Administration (FDA) on March 31, 2021 for the...
Countries Restrict AstraZeneca Vaccine for Younger Adults
Amid concerns over clotting risks, German and Canadian health officials have restricted usage of the AstraZeneca COVID-19 vaccine in people under the age of...
Investigation Finds Hemophilia Gene Therapy Likely Did Not Cause Hepatocellular Carcinoma
An investigation found that etranacogene dezaparvovec was unlikely to have caused a case of hepatocellular carcinoma (HCC) in a participant of the HOPE-B trial,...
Daunorubicin and Cytarabine Combination Approved for Pediatric Secondary AML
The U.S. Food and Drug Administration (FDA) has approved a revised label for liposomal daunorubicin and cytarabine, CPX 351, to include a new indication...
Current Issue
April 2021 Volume 7 Issue 5
This issue examines long-haul COVID-19, central nervous system relapse in non-Hodgkin lymphoma, and more.